CWM
CYTK icon

Congress Wealth Management’s Cytokinetics CYTK Stock Holding History

Congress Wealth Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$1.52M Buy
46,130
+18,130
+65% +$631K 0.01% 609
2025
Q1 		$1.13M Buy
+28,000
New +$1.29M 0.01% 608

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Congress Wealth Management's CYTK Position: Q2 2025 in Review

Congress Wealth Management increased its Cytokinetics (CYTK) stake by 65% in Q2 2025, buying an estimated $631K and bringing the position to 46,130 shares worth $1.52M. The position accounts for 0.01% of the portfolio, ranked #609.

Congress Wealth Management first reported a position in CYTK in Q1 2025 and has held it in 2 quarters since. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

  • Congress Wealth Management held 46,130 shares of Cytokinetics worth $1.52M as of Q2 2025.
  • Congress Wealth Management bought 18,130 Cytokinetics shares in Q2 2025, an estimated $631K.
  • Cytokinetics made up 0.01% of Congress Wealth Management's portfolio in Q2 2025, its #609 holding.
  • Congress Wealth Management first reported a position in Cytokinetics in Q1 2025 and has held it in 2 quarters since.
  • 311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on Congress Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.